Beta Drugs Reports Strong H1 FY27 Performance with 29% Topline Growth
Beta Drugs Ltd 路 Intimation 路 22 Oct 2026, 5:41 pm
Beta Drugs Reports Strong H1 FY27 Performance with 29% Topline Growth Beta Drugs posted strong H1 FY27 results, with revenue rising 29.2% YoY to INR 263 Cr and PAT increasing to INR 34 Cr (13.1% margin). EBITDA grew to INR 61 Cr with margins improving slightly to 23.2%, while gross margin expanded to 56.2% and ROCE reached 23.3%. Segment-wise, CMO led with INR 95 Cr (+21% YoY), Branded Products generated INR 71 Cr (+17% YoY), Exports rose to INR 43 Cr with 35 approvals, and Nivian surged 75% YoY to INR 31 Cr. Total borrowings declined significantly to INR 49 Cr.
Original exchange filing (PDF)
More announcements from Beta Drugs Ltd
- BETA DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 19-Nov-2026 to consider Other business. 路 16 Nov 2026
- To consider other business matters 路 16 Nov 2026
- Monitoring Agency Report as on 30th September, 2026 路 12 Nov 2026
- Beta Drugs Limited has informed the Exchange about Transcript 路 28 Oct 2026
- Beta Drugs Limited has informed the Exchange about Link of Recording 路 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 路 22 Oct 2026
- Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 22 Oct 2026
- Beta Drugs Limited has informed the Exchange about Schedule of meet 路 22 Oct 2026
